Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile to Present at the 21st Annual BioCentury NewsMakers Conference
PRINCETON, N.J., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive...
Toggle Summary Agile Initiates Phase 3 SECURE Study for Twirla(TM)
Twirla (AG200-15) is a Novel Low-Dose Combined Hormonal Contraceptive Patch Designed Using the Company's Proprietary Transdermal Skinfusion ® Technology Confirmatory SECURE Study To Build Upon Data From Previous Phase 3 Studies in Support of the Company's New Drug Application to the U.S....
Toggle Summary Agile Therapeutics to Ring the NASDAQ Stock Market Closing Bell
PRINCETON, N.J. , Sept. 2, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Mr....
Toggle Summary Agile Therapeutics Reports Second Quarter 2014 Financial Results
Company on Track With Initiation of Confirmatory Phase 3 Clinical Trial of Twirla(TM) in Third Quarter of 2014...
Toggle Summary Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion®
Intellectual Property Portfolio Broadened for Its Proprietary Transdermal Delivery System...
Toggle Summary Agile Therapeutics Joins Russell Microcap® Index
PRINCETON, N.J. , June 30, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , (NASDAQ: AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced it has been added to the Russell Microcap Index....
Toggle Summary Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion® Transdermal Delivery Device
Expands Patent Portfolio for its Contraceptive Patch, Twirla™...
Toggle Summary Agile Therapeutics to Participate at the Janney Capital Markets Boston Healthcare 1X1 Corporate Access Day
PRINCETON, N.J. , June 18, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , (NASDAQ: AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari , the Company's Chief Executive...
Toggle Summary Agile Therapeutics Announces Pricing Of Initial Public Offering
PRINCETON, N.J. , May 22, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced the pricing of its initial public offering of 9,166,667 shares of...
Toggle Summary Agile Therapeutics Files Registration Statement for Proposed Initial Public Offering
Shadow